long-acting VPAC2 agonist (Transition Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namelong-acting VPAC2 agonist (Transition Therapeutics)
Drug Alias NameFM-TP2000 seriesTP-107 (TheraPei)long-acting VPAC2 agonist (Forbes Medi-Tech)long-acting VPAC2 agonist (TheraPei)TP-107
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasoactive intestinal polypeptide receptor 2 agonistsInsulin release stimulants
TargetsInsulin receptorVasoactive intestinal polypeptide receptor 2
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTheraPei Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheraPei Pharmaceuticals IncTransition Therapeutics IncForbes Medi-Tech
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A